Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors

被引：111

作者：

Piezzo, Michela ^{[1
]}

Cocco, Stefania ^{[1
]}

Caputo, Roberta ^{[1
]}

Cianniello, Daniela ^{[1
]}

Di Gioia, Germira ^{[1
]}

Di Lauro, Vincenzo ^{[1
]}

Fusco, Giuseppina ^{[1
]}

Martinelli, Claudia ^{[2
]}

Nuzzo, Francesco ^{[1
]}

Pensabene, Matilde ^{[1
]}

De Laurentiis, Michelino ^{[1
]}

机构：

[1] Ist Nazl Tumori IRCCS Fdn G Pascale, Dept Breast & Thorac Oncol, Div Breast Med Oncol, I-80131 Naples, Italy

[2] Univ Naples Federico II, Dept Clin Med & Surg, I-80131 Naples, Italy

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2020年 / 21卷 / 18期

关键词：

cell cycle; cyclin-dependent kinase; cancer; metastatic breast cancer; hormone therapy; CDK4; 6; inhibitors; hormone receptors; therapies; DEPENDENT KINASE 4/6; ANTITUMOR-ACTIVITY; OPEN-LABEL; ENDOCRINE RESISTANCE; 1ST-LINE TREATMENT; PLUS PALBOCICLIB; PHASE-II; COMBINATION; FULVESTRANT; ABEMACICLIB;

D O I：

10.3390/ijms21186479

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Deregulation of cell cycle, via cyclin D/CDK/pRb pathway, is frequently observed in breast cancer lending support to the development of drugs targeting the cell cycle control machinery, like the inhibitors of the cycline-dependent kinases (CDK) 4 and 6. Up to now, three CDK4/6 inhibitors have been approved by FDA for the treatment of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer. These agents have been effective in improving the clinical outcomes, but the development of intrinsic or acquired resistance can limit the efficacy of these treatments. Clinical and translational research is now focused on investigation of the mechanism of sensitivity/resistance to CDK4/6 inhibition and novel therapeutic strategies aimed to improve clinical outcomes. This review summarizes the available knowledge regarding CDK4/6 inhibitor, the discovery of new biomarkers of response, and the biological rationale for new combination strategies of treatment.

引用

页码：1 / 23

页数：23

共 50 条

[1] The Role of CDK4/6 Inhibitors in Breast Cancer
Murphy, Conleth G.
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2019, 20 (06)
[2] Targeting CDK4/6 pathways and beyond in breast cancer
Ribnikar, Domen
Volovat, Simona Ruxandra
Cardoso, Fatima
BREAST, 2019, 43 : 8 - 17
[3] CDK4/6 inhibitors in breast cancer
Dukelow, Tim
Kishan, Divya
Khasraw, Mustafa
Murphy, Conleth G.
ANTI-CANCER DRUGS, 2015, 26 (08) : 797 - 806
[4] Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
Wu, Yanmei
Zhang, Yu
Pi, Hao
Sheng, Yuan
CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3477 - 3487
[5] CDK4/6 inhibitors in advanced breast cancer, what is beyond?
Mohammed, Amrallah A.
Rashied, Hanaa
Elsayed, Fifi Mostafa
ONCOLOGY REVIEWS, 2019, 13 (02) : 125 - 133
[6] CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities
Lynce, Filipa
Shajahan-Haq, Ayesha N.
Swain, Sandra M.
PHARMACOLOGY & THERAPEUTICS, 2018, 191 : 65 - 73
[7] CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer
Cetin, Bulent
Wabl, Chiara A.
Gumusay, Ozge
FUTURE ONCOLOGY, 2022, 18 (09) : 1143 - 1157
[8] The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer
Shah, Ami N.
Cristofanilli, Massimo
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (01)
[9] CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge
de Melo Gagliato, Debora
Buzaid, Antonio C.
Manuel Perez-Garcia, Jose
Llombart, Antonio
Cortes, Javier
CANCERS, 2020, 12 (09) : 1 - 19
[10] Incorporating CDK4/6 Inhibitors in the Treatment of Advanced Luminal Breast Cancer
Echavarria, Isabel
Jerez, Yolanda
Martin, Miguel
Lopez-Tarruella, Sara
BREAST CARE, 2017, 12 (05) : 296 - 302

← 1 2 3 4 5 →